Global Immuno-oncology Treatment Devices and Drugs Market Size, Forecast, and Trend Highlights Over 2025-2037
Immuno-oncology Treatment Devices and Drugs Market size was valued at USD 98.9 billion in 2024 and is projected to reach USD 380.6 billion by the end of 2037, rising at a CAGR of 13.2% during the forecast period, i.e., 2025-2037. In 2025, the industry size of immuno-oncology treatment devices and drugs is evaluated at USD 111.5 billion.
The global market is witnessing significant growth driven by the increasing cancer burden and the growing demand for immuno-diagnostic devices. In this regard, the World Health Organization’s 2024 report projects more than 29 million annual cancer cases by 2030, which is a 19.4 million upsurge from 2020. This has created an appreciable necessity for CAR-T therapies and checkpoint inhibitors. Besides, NCI in 2024 notes that 62% of late-stage cancers are currently eligible for immunotherapy, which marks a 42% up from 2015, reflecting the heightened adoption. To meet this, the APIs for these drugs are being drawn from the U.S., Germany, and China.
The current dynamics in the immuno-oncology treatment devices and drugs market are further carried out by research initiatives and trade activities. In this regard, NIH in 2024 assigned USD 26 billion towards immune oncology, out of which 66% was allocated towards clinical trials. Meanwhile Cancer Moonshot Initiative allocated USD 2.6 billion, aiming to accelerate immunotherapy adoption. WTO in 2024 states that the U.S. and EU are critical exporters of finished therapeutics, meanwhile China and India are leading the market with API production accounting for 45% of exports across the world. This wider market scope readily allows businesses in this sector.
Immuno-oncology Treatment Devices and Drugs Sector: Growth Drivers and Challenges
Growth Drivers
-
Industry partnerships: The efficiency of products in immuno-oncology treatment devices and drugs market encourages the firms to undertake significant collaborations, contributing to market expansion. For instance, in 2024, Merck announced a partnership with the NHS that resulted in Keytruda expansion to 50,ooo additional patients in the U.S. Besides, Roche acquired a biotech firm to enhance its T-cell engager portfolio, thereby anticipating USD 2.1 billion in added revenue by 2027. Therefore, such collaborations reduce the production costs and facilitate global distribution of the products.
-
Heightened technological advancements: There is an accelerated progress in the immuno-oncology treatment devices and drugs market, owing to the innovations in drug delivery and diagnostic procedures. A NIH study in 2024 records that Smart infusion pumps with IoT connectivity resulted in improved patient outcomes by 32%. Besides, the U.S. FDA approved 10 new AI-based diagnostic tools in 2024 for the identification of immunotherapy-responsive tumors. Hence, such milestones reduce treatment delays, projecting a positive market development with optimized dosing.
Historical Patient Growth (2010-2020) and Its Impact on Future Market Expansion
There has been a transformative growth in the immuno-oncology treatment devices and drugs market owing to the expanded patient pool over the last decade. Particularly, cancer screening, biomarker testing, and early immunotherapy approvals have amplified the adoption among eligible patients. Additionally, in the context of the established markets such as the U.S., EU, and Japan, which rely on new diagnostics, while China and India witnessed growth due to improved healthcare access, for a rising burden. Pricing and reimbursement policies remained crucial in Germany, allowing appropriate market penetration.
Below are the 2010-2020 patient growth data that underpins these trends, i.e., patients treated with immuno-oncology drugs, in millions:
|
Country |
2010 |
2020 |
CAGR (2010-2020) |
|
U.S. |
0.14 |
1.12 |
24.9% |
|
Germany |
0.07 |
0.67 |
29.2% |
|
France |
0.06 |
0.53 |
28.8% |
|
Spain |
0.04 |
0.32 |
31.2% |
|
Australia |
0.03 |
0.20 |
33.4% |
|
Japan |
0.10 |
0.72 |
24.3% |
|
India |
0.007 |
0.27 |
48.1% |
|
China |
0.05 |
0.92 |
40.6% |
Immuno-oncology treatment devices and drugs market expansion: Feasibility models and competitive strategies
The alignment of global leaders with the key trends and consumer preferences is shaping the immuno-oncology treatment devices and drugs market. The measurable success across all nations is proven to be achieved with localized manufacturing, expansion into emerging markets, and opting for innovative technologies. With a focus on domestic expansion from 2020, biosimilar production in India rose by 50%, as reported by ICMR. In Germany, the emergence of price reforms in 2022 led to a 30% increase in immunotherapy adoption.
Revenue Feasibility Models (2020-2024)
|
Expansion Model |
Key Region |
Implementation |
Revenue Impact |
|
Localized Manufacturing |
India |
API + finished drug production |
$2.2 billion market expansion |
|
Diagnostic Integration |
U.S. |
Companion Dx mandates |
42% Rx increase |
|
Tiered Pricing |
China |
Domestic price controls |
67% access improvement |
|
Hospital Partnerships |
Germany |
Value-based contracts |
€851 million savings |
Challenges
- Expensive treatment procedures: There is a limited reimbursement towards cancer treatment, which hinders patient accessibility in almost all nations. It is noted that the cost associated with CAR-T cell therapies, such as tisagenlecleucel, is approximately $529,200, which in total reaches $511,50 in a span of 90 days post-infusion. Regardless of the presence of reimbursement, it covers only a particular portion of treatment costs, making it challenging for patients to afford it, further deterring growth in the immuno-oncology treatment devices and drugs market.
Immuno-oncology Treatment Devices and Drugs Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
13.2% |
|
Base Year Market Size (2024) |
USD 98.9 billion |
|
Forecast Year Market Size (2037) |
USD 380.6 billion |
|
Regional Scope |
|
Immuno-oncology Treatment Devices and Drugs Segmentation
Product (Drugs, Devices)
Based on product, the drugs segment is expected to garner a lucrative share of 53.7% in the immuno-oncology treatment devices and drugs market by the end of 2037. The dominance of the segment is highly attributed to its continuous and widespread usage across all nations. For instance, in 2023, a clinical study by AHRQ found that the checkpoint inhibitors can save hospitalization costs by USD 9,000 per patient annually. Besides, the U.S. FDA’s accelerated approvals, i.e., 8 new indications from 2023 to 2025, expanded access to 26% of patients, further propelling the segment’s dominance.
End user (Hospitals, Specialty Clinics, Research Institutes)
Based on the end user, the hospitals segment is projected to grow at a considerable rate, with a share of 45.3% in the immuno-oncology treatment devices and drugs market in the assessed timeline. Hospitals play a critical role in cancer treatment owing to the presence of advanced equipment in these settings. As a result, the segment is subject to growth in support of coverage for inpatient immunotherapy procedures, which increased hospital adoption by 20% as of the CMS 2024 report. Besides, more than 58% of hospitals in the U.S. comprise dedicated immune oncology units, further reflecting a positive outlook for the segment’s growth.
Our in-depth analysis of the immuno-oncology treatment devices and drugs market includes the following segments:
|
Product |
|
|
Application |
|
|
End user |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Immuno-oncology Treatment Devices and Drugs Industry - Regional Synopsis
North America Market Analysis
The North America immuno-oncology treatment devices and drugs market is predicted to capture the largest share of 48.8% over the forecasted timeframe. The region’s dominance is primarily attributable to the heightened Medicare expansion covering 86% of drugs and the improved healthcare expenditure. The efforts from countries such as the U.S. and Canada stand out at the forefront for this upliftment. Besides, the checkpoint inhibitors draw 62% of the U.S. medical spending, reflecting the increased adoption. Meanwhile, the 2023 Inflation Reduction Act extended its support to lower the expenses to USD 2,000 in a year, boosting patient accessibility.
Canada complements the regional expansion of North America's immuno-oncology treatment devices and drugs market, driven by the improved outcomes in terms of AI-based diagnostics. Market in the country rises at 9.7% CAGR owing to the enhanced provincial healthcare investments, which is USD 1.2 billion, and public funding is covering 76% of drugs, persisting in a positive support. To reduce reliance on imports, Health Canada in 2025 launched CAR-T production, thereby contributing to the strong propagation in the sector.
Europe Market Statistics
Europe in the immuno-oncology treatment devices and drugs market is poised to hold the second largest share of 30.3%, rising at a CAGR of 10.2%, with the strong presence of key market players such as Germany and the U.K. In this regard, the EU Cancer Mission allocated a significant amount of €4.2 billion for research and development in terms of immunotherapy from 2021, offering 13% annual growth in immune-oncology adoption. Besides, on the regulatory front, the EU Health Data Space is currently integrating real-world evidence to optimize the prescription of I-O, which appreciably reduces delay by 6 months.
There is a huge opportunity for the immuno-oncology treatment devices and drugs market in the U.K., which holds 28.4% of the share in the European market. The region benefits from a huge patient pool; As per the NHS report in 2023, 26,000 patients in the country received immune oncology therapies, which reflects the accelerated demand. Besides, the budget allocation also plays a crucial role in the industry upliftment, with 10% of the NHS cancer budget being spent on immune oncology, which is £1.3 billion. Therefore, the existence of these factors as growth drivers remarkably sets standards for expansion.
Companies Dominating the Immuno-oncology Treatment Devices and Drugs Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
Key organizations in the immuno-oncology treatment devices and drugs market are making contributions towards the expansion by adopting numerous feasible strategies. The global market is witnessing dominance in terms of Europe and the U.S.-based firms, such as Merck, BMS, Roche, that are leveraging checkpoint inhibitors. Besides acquisitions and partnerships, such as Sanofi and Regeneron, have amplified innovation in cell and gene therapies. Furthermore, AI-based drug discovery with the integration of authentic evidence is the key differentiator for future growth.
Some of the prominent players are:
|
Company Name |
Country |
Market Share (2024) |
Industry Focus |
|
Merck & Co. |
U.S. |
24% |
Leader in checkpoint inhibitors (Keytruda) and combination therapies. |
|
Bristol-Myers Squibb |
U.S. |
20.6% |
Focus on Opdivo (PD-1 inhibitor) and CAR-T cell therapies. |
|
Roche (Genentech) |
Switzerland |
17.2% |
Dominates with Tecentriq and companion diagnostics (Ventana PD-L1 assays). |
|
Novartis |
Switzerland |
12% |
Pioneers in CAR-T (Kymriah) and TCR therapies. |
|
Johnson & Johnson |
U.S. |
10% |
Key player in Darzalex (multiple myeloma) and bispecific antibodies. |
|
Pfizer |
U.S. |
xx% |
Expanding in mRNA cancer vaccines (BioNTech partnership). |
|
AstraZeneca |
UK |
xx% |
Focus on Imfinzi (PD-L1 inhibitor) and lung cancer immunotherapies. |
|
Gilead Sciences |
U.S. |
xx% |
Leader in cell therapy (Yescarta, Tecartus). |
|
Amgen |
U.S. |
xx% |
Developing bispecific T-cell engagers (Blincyto). |
|
Sanofi |
France |
xx% |
Investing in next-gen cancer vaccines and immune checkpoint modulators. |
|
Takeda Pharmaceutical |
Japan |
xx% |
Focus on hematologic cancers and ADC (antibody-drug conjugate) therapies. |
|
Daiichi Sankyo |
Japan |
xx% |
Advancing ADCs (Enhertu) and immuno-oncology combos. |
|
Eli Lilly |
U.S. |
xx% |
Expanding PD-1/PD-L1 portfolio through acquisitions (Loxo Oncology). |
|
GSK |
UK |
xx% |
Developing personalized cancer vaccines and immune-oncology small molecules. |
|
BeiGene |
China |
xx% |
Leading in China with tislelizumab (PD-1 inhibitor). |
|
Hengrui Pharma |
China |
xx% |
Major biosimilar developer (camrelizumab). |
|
Celltrion |
South Korea |
xx% |
Focus on biosimilars for checkpoint inhibitors. |
|
CSL (Seqirus) |
Australia |
xx% |
Investing in mRNA-based immuno-oncology platforms. |
|
Dr. Reddy’s Laboratories |
India |
xx% |
Developing affordable biosimilars for emerging markets. |
|
Pharmaniaga |
Malaysia |
xx% |
Localized production of cancer immunotherapies for ASEAN markets. |
Below are the areas covered for each company under the top 15 global manufacturers:
Recent Developments
- In May 2024, Novartis launched Kymriah (CAR-T) for refractory follicular lymphoma. It is reported that its EMA approval increased Novartis’ EU CAR-T revenue by 16%, targeting innumerable patients annually.
- In March 2024, Merck & Co. launched KEYTRUDA (pembrolizumab) for early-stage NSCLC, which is approved by the U.S. FDA for Stage IB-IIIA non-small cell lung cancer. The launch expanded Merck’s market share by 10% in the second quarter of 2024.
- Report ID: 2940
- Published Date: Jun 05, 2025
- Report Format: PDF, PPT
Have specific data needs or budget constraints?
Reach out to us for a customized quote or to learn more about our special pricing
for startups and universities
Frequently Asked Questions (FAQ)
Immuno-oncology Treatment Devices and Drugs Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
